REFERENCES:

- [1] Brandt D, Sohr E, et al. CD14+ monocytes contribute to inflammation in chronic nonbacterial osteomyelitis (CNO) through increased NLRP3 inflammasome expression. *Clin Immunol*. 2018 Nov;196:77-84.
- [2] Hofmann SR, Schnabel A, et al. Chronic Nonbacterial Osteomyelitis: Pathophysiological Concepts and Current Treatment Strategies. *J Rheumatol*. 2016 Nov;43(11):1956-1964.
- [3] Hofmann SR, Kubasch AS, et al. Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1 β expression and release. *Clin Immunol*. 2015 Dec;161(2):300-7.
- [4] Zhao Y, Wu EY, et al. Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. *Arthritis Care Res (Hoboken)*. 2018 Aug;70(8):1228-1237.
- [5] Ferguson PJ, Laxer RM. New discoveries in CRMO: IL-1 β , the neutrophil, and the microbiome implicated in disease pathogenesis in Pstpip2-deficient mice. *Semin Immunopathol*. 2015 Jul;37(4):407-12.
- [6] Cox AJ, Darbro BW, et al. Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO). *PLoS One*. 2017 Mar 16;12(3):e0169687.

Disclosure of Interests: Christian Hedrich Grant/research support from: Novartis Pharmaceuticas for Research study on effector T cells in psoriasis, Speakers bureau: In 2016: Roche Pharmaceuticals, Rheumatologisch, Dresden, Germany; Novartis, Advisory board > Travel costs.

DOI: 10.1136/annrheumdis-2019-eular.8494

SP0188 SAPHO – AN ADULT PERSPECTIVE

Gunter Assmann. University Medical School of Saarland, Medicine I, Oncology and Rheumatology, Homburg, Germany

Background: The acronym SAPHO has been introduced to describe a syndrome in adolescents and adults suffering from synovitis (arthritis), acne, pustulosis, hyperostosis, and non-bacterial osteitis preferentially in the sternal region. Currently, this also includes the entity CNO with non-bacterial chronic recurrent multifocal osteomyelitis (CRMO) in cases which primarily occur in adult age.

Objectives: The diagnostic certainty of SAPHO syndrome in case of incomplete presentation of the clinical features has been unclear so far. Furthermore, the treatment approach of SAPHO syndrome is difficult because the etiology remains unknown, although a reactive infectious osteitis in genetic predisposed subjects seems appealing.

Methods: Here we present relevant case series of SAPHO patients which should elucidate the relevance of different diagnostic procedures and treatment options. It has been noted, however, that particularly in respect of the use of antirheumatic drugs case series with predominantly small numbers of SAPHO patients suggest different treatment approaches.

Results: The diagnosis of SAPHO syndrome is made not only in the full picture of the disease according to the acronym, but also in non-bacterial and non-malignant osteitis with hyperostosis with simultaneous or delayed onset of acne, psoriasis and/or PPP. In addition, the primary manifestation of CNO in adulthood is nowadays classified as SAPHO syndrome. Recent studies have previously confirmed the usefulness of skeletal scintigraphy in 2 phases as a diagnostic. Imaging with MRI is frequently used preferentially for the assessment of osteitis activity, CT for the assessment of destruction and hyperostosis. The CT-guided biopsy of the lesion should be performed in solitary manifestation of osteitis. Basically, SAPHO syndrome has a high impact on patients' general health resulting in high burden of

disease. There are many approaches to drug therapy, but only a few have been investigated in larger case series - none of them as controlled studies. Smaller case series of less than 10 patients reported limited efficacy of DMARD with MTX, azathioprine, or ciclosporin. Studies with larger case numbers show a moderate efficacy of bisphosphonates as well as TNF-alpha blockers. A short-term but not sustained effect has been demonstrated for the antibiotic azithromycin, as well as for steroids per os or as infiltration into osteitis. Referring to the treatment approach in SpA newly approved biologicals with IL-17 or IL-12/23 blocking effects demonstrated promising results in individual case reports of SAPHO patients.

Conclusion: Modern diagnostic imaging methods are increasingly being used for SAPHO syndrome. The selection of potentially effective drugs for SAPHO syndrome has increased. However, prospective studies to develop guidelines for the diagnosis and therapy of SAPHO syndrome are still lacking. Until further notice, the therapy is based on the recommendations for psoriatic arthritis or spondyloarthritis.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.8420

SATURDAY, 15 JUNE 2019

09:00:00 – 10:50:00

EULAR Projects in clinical affairs

SP0189 UPDATE ON EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SLE

Antonis Fanouriakis. "Attikon" University Hospital, Rheumatology and Clinical Immunology, Athens, Greece

Background: Recent advances in treatment strategies and goals of treatment in systemic lupus erythematosus (SLE) called for an update of the EULAR recommendations for the disease, capitalizing on the strengths of and experience from similar previous projects.

Objectives: To update the EULAR recommendations for the management of SLE

Methods: Systematic literature review (01/2007-12/2017) followed by modified Delphi method to form questions, elicit expert opinions and reach consensus.

Results: Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all lupus patients, at a dose not exceeding 5mg/kg real body weight. During chronic maintenance treatment, glucocorticoids should be minimized to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of glucocorticoids. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. SLE patients should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile, and preventative strategies be tailored accordingly.

Conclusion: The recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.

Disclosure of Interests: Antonis Fanouriakis Paid instructor for: Amgen, GSK, Speakers bureau: Abbvie, Enorasis, Genesis Pharma

DOI: 10.1136/annrheumdis-2019-eular.8473